Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 4:11:6163-6173.
doi: 10.2147/CMAR.S208839. eCollection 2019.

Modified Glasgow prognostic score as a prognostic factor for renal cell carcinomas: a systematic review and meta-analysis

Xu Hu #  1 , Yan Wang #  1 , Wei-Xiao Yang #  1 , Wei-Chao Dou  1 , Yan-Xiang Shao  1 , Xiang Li  2
Affiliations

Modified Glasgow prognostic score as a prognostic factor for renal cell carcinomas: a systematic review and meta-analysis

Xu Hu et al. Cancer Manag Res. .

Abstract

Objective: The modified Glasgow prognostic score (mGPS), a combination of C-reactive protein (CRP) and albumin levels, reflects systemic inflammation and nutritional status. This score has been shown to have prognosis value for various tumors. In the present study, we evaluated the prognostic value of mGPS for patients with renal cell carcinoma (RCC).

Methods: Literature search was conducted based on PubMed, Embase, and Cochrane Central Register of Controlled Trials up to December 2018. We pooled HRs and 95% CIs to evaluate the correlation between mGPS and survival in patients with RCC.

Results: Twelve studies comprising 2,391 patients were included in the present study for quantitative synthesis. Our studies demonstrated that higher mGPS was significantly correlated to poor overall survival (HR=4.31; 95%CI, 2.78-6.68; P<0.001), cancer-specific survival (HR=5.88; 95%CI, 3.93-8.78; P<0.001), recurrence-free survival (HR=3.15; 95%CI, 2.07-4.79; P<0.001), and progression-free survival (HR=1.91; 95%CI, 1.27-2.89; P=0.002). Subgroup analyses also confirmed the overall results.

Conclusion: mGPS could serve as a predictive tool for the survival of patients with RCC. In the different subgroups, the results are also consistent with previous results. In conclusion, pretreatment higher mGPS is associated with poorer survival in patients with RCC. Further external validations are necessary to strengthen this concept.

Keywords: meta-analysis; modified Glasgow prognostic score; prognosis; renal cell carcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Flowchart of literature search.
Figure 2
Figure 2
Association between mGPS and OS in patients with renal cell carcinoma. Abbreviations: HR, hazard ratio; CI, confidence interval; mGPS, modified Glasgow prognostic score; OS, overall survival.
Figure 3
Figure 3
Association between mGPS and CSS in patients with renal cell carcinoma. Abbreviations: HR, hazard ratio; CI, confidence interval; mGPS, modified Glasgow prognostic score; CSS, cancer-specific survival.
Figure 4
Figure 4
Association between mGPS and RFS in patients with renal cell carcinoma. Abbreviations: HR, hazard ratio; CI, confidence interval; mGPS, modified Glasgow prognostic score; RFS, recurrence-free survival.
Figure 5
Figure 5
Association between mGPS and PFS in patients with renal cell carcinoma. Abbreviations: HR, hazard ratio; CI, confidence interval; mGPS, modified Glasgow prognostic score; PFS, progression-free survival.
Figure 6
Figure 6
Sensitivity analyses of the association between mGPS and OS (A), CSS (B), and RFS (C) in patients with renal cell carcinoma. Abbreviations: CI, confidence interval; mGPS, modified Glasgow prognostic score; OS, overall survival; CSS, cancer-specific survival; RFS, recurrence-free survival.
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492 - DOI - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. doi: 10.3322/caac.21387 - DOI - PubMed
    1. Brookman-May SD, May M, Shariat SF, et al. Time to recurrence is a significant predictor of cancer-specific survival after recurrence in patients with recurrent renal cell carcinoma–results from a comprehensive multi-centre database (CORONA/SATURN-Project). BJU Int. 2013;112(7):909–916. doi: 10.1111/bju.12246 - DOI - PubMed
    1. You D, Jeong IG, Ahn JH, et al. The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy. J Urol. 2011;185(1):54–59. doi: 10.1016/j.juro.2010.09.018 - DOI - PubMed
    1. Chen DY, Uzzo RG, Viterbo R. Thinking beyond surgery in the management of renal cell carcinoma: the risk to die from renal cell carcinoma and competing risks of death. World J Urol. 2014;32(3):607–613. - PubMed